Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Neurodegenerative Disorder Therapeutics Market Report 2024

Neurodegenerative Disorder Therapeutics Global Market Report 2025 – By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types), By Drug Type (N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types), By Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2025-2034

Neurodegenerative Disorder Therapeutics Global Market Report 2025

Report Price : $4490.00 | Pages : 250 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Neurodegenerative Disorder Therapeutics Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Neurodegenerative Disorder Therapeutics Market Definition

Neurodegenerative disorder therapeutics refers to a medication or gene therapy to treat patients with neurodegenerative disorders therapeutically by directly rectifying pathogenic pathways, through neuroprotection, neurorestoration, and symptom control.

The main drug types of neurodegenerative disorder therapeutics are n- methyl d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, and others. Selective serotonin reuptake inhibitors are a type of medication that is commonly used to treat depression and a few other mental illnesses. The various indications include Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington’s disease, and other indications that ARE distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Neurodegenerative Disorder Therapeutics Market Segmentation

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson's Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer's Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington's Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Neurodegenerative Disorder Therapeutics Market Size and growth rate 2025 to 2029: Graph

Neurodegenerative Disorder Therapeutics Market Size 2025 And Growth Rate

The neurodegenerative disorder therapeutics market size has grown strongly in recent years. It will grow from $18.53 billion in 2024 to $20.04 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to aging population, rising prevalence of neurodegenerative disorders, increasing life expectancy, rising investments from pharmaceutical companies, awareness and advocacy.

Neurodegenerative Disorder Therapeutics Market Growth Forecast

The neurodegenerative disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $28.33 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to rising demand for personalized medicine, targeted therapy, increasing availability of clinical trials, rising healthcare expenditure. Major trends in the forecast period include disease-modifying therapies, non-pharmacological interventions, telemedicine and remote monitoring, technological innovations, precision therapeutics, digital health solutions, biomarker-driven trials.

Book your 30 minutes free consultation with our research experts

Contact Us

Neurodegenerative Disorder Therapeutics Market Driver: Growing Prevalence Of Neurodegenerative Disorders Fuels Neurodegenerative Disorder Therapeutics Market

The increased prevalence of neurodegenerative among the global population contributes to the growth of the neurodegenerative disorder therapeutics market. The increase in the geriatric population is attributed to the increased prevalence of neurodegenerative disorders. For instance, in 2024, According to World Population Prospects, the number of people above 60 years of age will increase to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple to 425 million in 2050. According to the Alzheimer’s Association, around 5.8 million Americans are suffering from Alzheimer’s disease, and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the aging population increases the demand for neurodegenerative disorder therapeutics thereby driving the neurodegenerative disorder therapeutics market.

Neurodegenerative Disorder Therapeutics Market Driver: Elevated R&D Investments Driving Growth In The Neurodegenerative Disorder Therapeutics Market

Increasing investment in research and development (R&D) for neurodegenerative disorder therapeutics is expected to propel the growth of the neurodegenerative disorder therapeutics market going forward. Investments in research and development for neurodegenerative disorders are launched by governments and organizations for various compelling reasons, including the increasing prevalence, significant unmet medical needs, economic repercussions, global health initiatives, and more. For instance, in March 2023, according to Government of Canada, a Canada-based federal administration, in 2023, the government of Canada revealed a $38.3 million investment aimed at advancing research into neurodegenerative diseases. Therefore, increasing investment in research and development (R&D) for neurodegenerative disorder therapeutics will continue to drive the growth of the neurodegenerative disorder therapeutics market in the forecast period.

Global Neurodegenerative Disorder Therapeutics Market Major Players

Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

Global Neurodegenerative Disorder Therapeutics Market Trend: Strategic Collaborations And Partnerships Driving Advancements In Neurodegenerative Disorder Therapeutics

Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non-government organizations to discover and develop therapeutics for a range of neurodegenerative diseases. The companies in the neurodegenerative disorder therapeutics market are also increasing their collaboration with other players in the market to increase their capabilities for research and development activities to develop new and more effective therapeutic solutions to treat neurodegenerative disorders. For instance, in July 2022, NRG Therapeutics, a UK-based drug discovery company focused on therapeutic approaches, partnered with Domainex, a UK-based drug discovery service, to develop neurodegenerative disease treatment. For the treatment of Parkinson's disease, motor neuron disease (MND), and other incapacitating chronic neurodegenerative conditions, the firms would work together to develop novel small-molecule disease-modifying medications.

Global Neurodegenerative Disorder Therapeutics Market Trend: Innovative Product Launch In The Neurodegenerative Disorder Therapeutics Market

Major companies operating in the neurodegenerative disorder therapeutics market are launching innovative techniques such as Neurofilament Light Chain (NfL) blood tests to gain a competitive edge in the market. The Neurofilament Light Chain (NfL) blood test empowers medical professionals to detect and confirm indications of neurodegenerative disorders. This advancement enables physicians to offer patients a more efficient and accurate route to diagnosis and treatment. For instance, in July 2022, Labcorp, a US-based company involved in drug development and drug testing, launched Neurofilament Light Chain (NfL) blood test that provides direct evidence of neuronal damage. Increased levels of NfL serve as an indicator of neuronal damage, whether resulting from conditions like multiple sclerosis, Alzheimer's, and Parkinson's disease, or due to brain injuries, including concussions. Neurofilament Light Chain (NfL) is a non-specific biomarker for several neurodegenerative conditions, including Alzheimer’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). NfL is a neuron-specific protein that is released into the extracellular space in response to neuronal injury and neurodegeneration.

Neurodegenerative Disorder Therapeutics Market Merger And Acquisition: VitalPath Acquired Modern Catheter Technologies

In January 2022, VitalPath, a US-based manufacturer of catheters and catheter shafts acquired Modern Catheter Technologies for an undisclosed amount. The acquisition will increase VitalPath's capacity for growth, bringing its entire manufacturing footprint to more than 80,000 square feet, including 35,000 square feet of ISO 7 and 8 cleanroom space. Modern Catheter Technologies is a US-based manufacturer of microcatheters used in neurovascular and electrophysiology.

Regional Outlook For The Global Neurodegenerative Disorder Therapeutics Market

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2024. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Defines the Neurodegenerative Disorder Therapeutics Market?

The neurodegenerative disorder therapeutics market includes revenues earned by entities by correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Neurodegenerative Disorder Therapeutics Industry?

The neurodegenerative disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative disorder therapeutics market statistics, including neurodegenerative disorder therapeutics industry global market size, regional shares, competitors with a neurodegenerative disorder therapeutics market share, detailed neurodegenerative disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disorder therapeutics industry. This neurodegenerative disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Neurodegenerative Disorder Therapeutics Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $20.04 billion
Revenue Forecast In 2034 $28.33 billion
Growth Rate CAGR of 9.0% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Indication Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Parkinson's Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
2) By Alzheimer's Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids
4) By Huntington's Disease: Tetrabenazine, Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Neurodegenerative Disorder Therapeutics Market Characteristics

    3. Neurodegenerative Disorder Therapeutics Market Trends And Strategies

    4. Neurodegenerative Disorder Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

    5. Global Neurodegenerative Disorder Therapeutics Growth Analysis And Strategic Analysis Framework

    5.1. Global Neurodegenerative Disorder Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Neurodegenerative Disorder Therapeutics Market Growth Rate Analysis

    5.4. Global Neurodegenerative Disorder Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Neurodegenerative Disorder Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Neurodegenerative Disorder Therapeutics Total Addressable Market (TAM)

    6. Neurodegenerative Disorder Therapeutics Market Segmentation

    6.1. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Parkinson's Disease

    Alzheimer's Disease

    Multiple Sclerosis

    Huntington Disease

    Other Indication Types

    6.2. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    N-methyl-D-aspartate Receptor

    Selective Serotonin Reuptake Inhibitor

    Dopamine Inhibitors

    Other Drug Types

    6.3. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    6.4. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Dopamine Agonists

    MAO-B Inhibitors

    COMT Inhibitors

    Anticholinergics

    6.5. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Cholinesterase Inhibitors

    NMDA Receptor Antagonists

    Anti-Amyloid Monoclonal Antibodies

    6.6. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Multiple Sclerosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Immunomodulators

    Immunosuppressants

    Corticosteroids

    6.7. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Tetrabenazine

    Antipsychotic Medications

    6.8. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Other Indication Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Amyotrophic Lateral Sclerosis (ALS) Treatments

    Frontotemporal Dementia Treatments

    Prion Disease Treatments

    7. Neurodegenerative Disorder Therapeutics Market Regional And Country Analysis

    7.1. Global Neurodegenerative Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Neurodegenerative Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Neurodegenerative Disorder Therapeutics Market

    8.1. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Neurodegenerative Disorder Therapeutics Market

    9.1. China Neurodegenerative Disorder Therapeutics Market Overview

    9.2. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Neurodegenerative Disorder Therapeutics Market

    10.1. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Neurodegenerative Disorder Therapeutics Market

    11.1. Japan Neurodegenerative Disorder Therapeutics Market Overview

    11.2. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Neurodegenerative Disorder Therapeutics Market

    12.1. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Neurodegenerative Disorder Therapeutics Market

    13.1. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Neurodegenerative Disorder Therapeutics Market

    14.1. South Korea Neurodegenerative Disorder Therapeutics Market Overview

    14.2. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Neurodegenerative Disorder Therapeutics Market

    15.1. Western Europe Neurodegenerative Disorder Therapeutics Market Overview

    15.2. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Neurodegenerative Disorder Therapeutics Market

    16.1. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Neurodegenerative Disorder Therapeutics Market

    17.1. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Neurodegenerative Disorder Therapeutics Market

    18.1. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Neurodegenerative Disorder Therapeutics Market

    19.1. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Neurodegenerative Disorder Therapeutics Market

    20.1. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Neurodegenerative Disorder Therapeutics Market

    21.1. Eastern Europe Neurodegenerative Disorder Therapeutics Market Overview

    21.2. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Neurodegenerative Disorder Therapeutics Market

    22.1. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Neurodegenerative Disorder Therapeutics Market

    23.1. North America Neurodegenerative Disorder Therapeutics Market Overview

    23.2. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Neurodegenerative Disorder Therapeutics Market

    24.1. USA Neurodegenerative Disorder Therapeutics Market Overview

    24.2. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Neurodegenerative Disorder Therapeutics Market

    25.1. Canada Neurodegenerative Disorder Therapeutics Market Overview

    25.2. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Neurodegenerative Disorder Therapeutics Market

    26.1. South America Neurodegenerative Disorder Therapeutics Market Overview

    26.2. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Neurodegenerative Disorder Therapeutics Market

    27.1. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Neurodegenerative Disorder Therapeutics Market

    28.1. Middle East Neurodegenerative Disorder Therapeutics Market Overview

    28.2. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Neurodegenerative Disorder Therapeutics Market

    29.1. Africa Neurodegenerative Disorder Therapeutics Market Overview

    29.2. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Neurodegenerative Disorder Therapeutics Market Competitive Landscape And Company Profiles

    30.1. Neurodegenerative Disorder Therapeutics Market Competitive Landscape

    30.2. Neurodegenerative Disorder Therapeutics Market Company Profiles

    30.2.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

    31. Neurodegenerative Disorder Therapeutics Market Other Major And Innovative Companies

    31.1. UCB S.A.

    31.2. F. Hoffmann-La Roche Ltd.

    31.3. ACADIA Pharmaceuticals Inc.

    31.4. H. Lundbeck A/S

    31.5. Boehringer Ingelheim International GmbH

    31.6. Merck Serono S.A.

    31.7. Orion Corporation

    31.8. Mitsubishi Tanabe Pharma America

    31.9. Allergan PLC

    31.10. GlaxoSmithKline PLC

    31.11. AbbVie Inc.

    31.12. Eli Lilly and Company

    31.13. Celgene Corporation

    31.14. Neuro-Hitech Inc.

    31.15. Bayer Schering Pharma AG

    32. Global Neurodegenerative Disorder Therapeutics Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Neurodegenerative Disorder Therapeutics Market

    34. Recent Developments In The Neurodegenerative Disorder Therapeutics Market

    35. Neurodegenerative Disorder Therapeutics Market High Potential Countries, Segments and Strategies

    35.1 Neurodegenerative Disorder Therapeutics Market In 2029 - Countries Offering Most New Opportunities

    35.2 Neurodegenerative Disorder Therapeutics Market In 2029 - Segments Offering Most New Opportunities

    35.3 Neurodegenerative Disorder Therapeutics Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Multiple Sclerosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Other Indication Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Neurodegenerative Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Neurodegenerative Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Biogen Inc. Financial Performance
  • Table 80: Pfizer Inc. Financial Performance
  • Table 81: Novartis International AG Financial Performance
  • Table 82: Sanofi S.A. Financial Performance
  • Table 83: Teva Pharmaceutical Industries Ltd. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Multiple Sclerosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Other Indication Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Neurodegenerative Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Neurodegenerative Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Biogen Inc. Financial Performance
  • Figure 80: Pfizer Inc. Financial Performance
  • Figure 81: Novartis International AG Financial Performance
  • Figure 82: Sanofi S.A. Financial Performance
  • Figure 83: Teva Pharmaceutical Industries Ltd. Financial Performance

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

Read More

The Biosimilar Therapeutic Peptides Market Share, Market Size, And Growth Rate 2022

Read More

Global Anticoagulants Market 2022 – Market Opportunities And Strategies

Read More

What Is The Compression Therapy Market Overview In 2022?

Read More

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the brain tumor drugs market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the biologics market research report 2022 with industry size, share, segments and market growth

Read More

Neurology Devices Global Market Report 2025 – By Type (Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Device), By Type of Expenditure (Public, Private), By Product (Instruments/Equipment, Disposables), By End User (Hospitals And Clinics, Diagnostic Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2025-203

View Report

Interventional Neurology Devices And Equipment Global Market Report 2025 – By Type (Aneurysm Coiling & Embolization Devices, Cerebrospinal Fluid Management Devices, Neurothrombectomy Devices, Support Devices), Aneurysm Coiling & Embolization Devices By Type (Embolic coils, Flow diversion devices, Liquid embolic devices), Angioplasty Devices by Type (Carotid artery stents, Embolic protection systems), Support Devices By Type, Micro guide wires, Micro catheters), Neurothrombectomy Devices By Type (CLOT retrieval devices, Suction and aspiration devices, Snare), By End-User (Hospitals, Neurology clinics, Ambulatory care centers and others) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Neurosurgery Devices And Equipment Global Market Report 2025 – By Device Type (Neuroendoscope, Stereotactic Systems, Aneurysm Clips, Neurostimulation Devices, Cerebrospinal Fluid Management Devices, Neurosurgical Evacuation Device, Neurosurgical Navigation Systems, Neurosurgery Surgical Power Tools, Others (Ultrasonic Aspirators, Surgical Instruments)), By Surgery Type (Intracranial Surgery, Endonasal Neurosurgery, Spinal Surgery), By End User (Hospitals, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Brain And Neuroimaging Devices Global Market Report 2025 – By Imaging Type (Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magneto Encephalography (MEG), Other Imaging Types), By Application (Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Other Applications), By End-user (Hospitals, Diagnostic Centres, Ambulatory Surgical Centres) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Neuroprosthetics Global Market Report 2025 – By Type (Motor Neuroprosthetics, Auditory Neuroprosthetics/ Cochlear implants, Visual Neuroprosthetics/ Retinal implants, Cognitive Neuroprosthetics ), By Technique (Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Transcranial Magnetic Stimulation ), By Application (Motor Neuron Disorders, Physiological Disorders, Cognitive Disorders ) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Cerebrospinal Fluid Management (CSF) Devices And Equipment Global Market Report 2025 – By Type (CSF Shunts, CSF Drainage Systems), By Age group (Pediatric, Adult, Geriatric), By End User (Hospitals, Ambulatory surgical centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Neurostimulation Devices Global Market Report 2025 – By Product (Implantable Devices, External Devices), By Application (Pain Management, Epilepsy, Essential Tremor, Urinary and Fecal Incontinence, Depression, Dystonia, Gastroparesis, Parkinson's Disease), By End User (Hospitals, Rehabilitation Centers, Medical Clinic) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Medical Equipment Global Market Report 2025 – By Type (In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices), By Type Of Expenditure (Public, Private), By Product (Instruments And Equipment, Disposables And Consumables), By End User (Hospitals And Clinics, Homecare And Diagnostic Centers, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Neurodegenerative Disorder Therapeutics market?

Neurodegenerative disorder therapeutics refers to a medication or gene therapy to treat patients with neurodegenerative disorders therapeutically by directly rectifying pathogenic pathways, through neuroprotection, neurorestoration, and symptom control. For further insights on the Neurodegenerative Disorder Therapeutics market, request a sample here

How will the Neurodegenerative Disorder Therapeutics market drivers and restraints affect the market dynamics? What forces will shape the Neurodegenerative Disorder Therapeutics industry going forward?

The Neurodegenerative Disorder Therapeutics market major growth driver - Elevated R&D Investments Driving Growth In The Neurodegenerative Disorder Therapeutics Market. For further insights on the Neurodegenerative Disorder Therapeutics market, request a sample here

What is the forecast market size or the forecast market value of the Neurodegenerative Disorder Therapeutics market?

The Neurodegenerative Disorder Therapeutics market size has grown strongly in recent years. The neurodegenerative disorder therapeutics market size has grown strongly in recent years. It will grow from $18.53 billion in 2024 to $20.04 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to aging population, rising prevalence of neurodegenerative disorders, increasing life expectancy, rising investments from pharmaceutical companies, awareness and advocacy. The neurodegenerative disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $28.33 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to rising demand for personalized medicine, targeted therapy, increasing availability of clinical trials, rising healthcare expenditure. Major trends in the forecast period include disease-modifying therapies, non-pharmacological interventions, telemedicine and remote monitoring, technological innovations, precision therapeutics, digital health solutions, biomarker-driven trials. For further insights on the Neurodegenerative Disorder Therapeutics market, request a sample here

How is the Neurodegenerative Disorder Therapeutics market segmented?

The neurodegenerative disorder therapeutics market covered in this report is segmented –
1) By Indication Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Parkinson's Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
2) By Alzheimer's Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids
4) By Huntington's Disease: Tetrabenazine, Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments For further insights on the Neurodegenerative Disorder Therapeutics market, request a sample here

Which region has the largest share of the Neurodegenerative Disorder Therapeutics market? What are the other regions covered in the report?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2024. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. For further insights on the Neurodegenerative Disorder Therapeutics market, request a sample here.

Who are the major players in the Neurodegenerative Disorder Therapeutics market?

Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc. . For further insights on the Neurodegenerative Disorder Therapeutics market, request a sample here.

What are the key trends in the Neurodegenerative Disorder Therapeutics market?

Major trends in the Neurodegenerative Disorder Therapeutics market include Innovative Product Launch In The Neurodegenerative Disorder Therapeutics Market. For further insights on the Neurodegenerative Disorder Therapeutics market, request a sample here.

What are the major opportunities in the Neurodegenerative Disorder Therapeutics market? What are the strategies for the Neurodegenerative Disorder Therapeutics market?

For detailed insights on the major opportunities and strategies in the Neurodegenerative Disorder Therapeutics market, request a sample here.

How does the Neurodegenerative Disorder Therapeutics market relate to the overall economy and other similar markets?

For detailed insights on Neurodegenerative Disorder Therapeutics's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Neurodegenerative Disorder Therapeutics industry?

For detailed insights on the mergers and acquisitions in the Neurodegenerative Disorder Therapeutics industry, request a sample here.

What are the key dynamics influencing the Neurodegenerative Disorder Therapeutics market growth? SWOT analysis of the Neurodegenerative Disorder Therapeutics market.

For detailed insights on the key dynamics influencing the Neurodegenerative Disorder Therapeutics market growth and SWOT analysis of the Neurodegenerative Disorder Therapeutics industry, request a sample here.